Canada Life’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Canada Life’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-538	Closed	-$11K	–	2807
2019 Q1	$11K	Hold	538	–	–	﹤0.01%	2399
2018 Q4	$7K	Hold	538	–	–	﹤0.01%	2605
2018 Q3	$20K	Hold	538	–	–	﹤0.01%	2508
2018 Q2	$19K	Hold	538	–	–	﹤0.01%	2526
2018 Q1	$25K	Hold	538	–	–	﹤0.01%	2484
2017 Q4	$20K	Hold	538	–	–	﹤0.01%	2504
2017 Q3	$29K	Hold	538	–	–	﹤0.01%	2446
2017 Q2	$30K	Hold	538	–	–	﹤0.01%	2443
2017 Q1	$29K	Hold	538	–	–	﹤0.01%	2416
2016 Q4	$31K	Hold	538	–	–	﹤0.01%	2430
2016 Q3	$33K	Hold	538	–	–	﹤0.01%	2411
2016 Q2	$30K	Hold	538	–	–	﹤0.01%	2425
2016 Q1	$34K	Hold	538	–	–	﹤0.01%	2254
2015 Q4	$76K	Buy	+538	New	+$73.1K	﹤0.01%	1942

Other funds holding KDNY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Canada Life's KDNY Position: Q2 2019 in Review

Canada Life sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2019, closing a stake of 538 shares — an estimated $11K sold.

Canada Life first reported a position in KDNY in Q4 2015 and held it in 14 quarters. The position peaked at $76K in Q4 2015. 97 funds tracked by Wall St. Rank hold KDNY as of Q2 2019.

Canada Life reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Canada Life sold 538 Chinook Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $11K.
Canada Life first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2015 and held it in 14 quarters.
Canada Life's Chinook Therapeutics, Inc. Common Stock position peaked at $76K in Q4 2015.
97 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Canada Life's 13F filing for Q2 2019, filed 31 Jul 2019.